Nebivolol is a beta-blocker and antihypertensive medication that has additional vasodilatory activity mediated by nitric oxide release. Nebivolol has yet to be linked to instances of clinically apparent liver injury.
Nebivolol (ne biv' oh lol) is an antihypertensive agent that has both beta-adrenergic receptor blocking activity and separate direct vasodilatory actions. The beta blockade is cardioselective, acting largely on beta-1 adrenergic receptors. Beta-1 adrenergic blockade reduces the heart rate and myocardial contractility by slowing the atrioventricular (AV) conduction and suppressing automaticity. Nebivolol also has vasodilatory activity that is not explained by typical beta blockade and appears to be mediated by release of nitric oxide from endothelial cells. Nebivolol was approved for use in the United States in 2007 and it is currently indicated for the management of hypertension either as monotherapy or in combination with other antihypertensive agents. Nebivolol is available in tablets of 2.5, 5, 10 and 20 mg under the trade name Bystolic. The typical initial oral dose in adults is 5 mg once daily, with subsequent dose modification based upon clinical response and tolerance; the total daily maintenance dose ranges from 5 to 40 mg. Common side effects of nebivolol include bradycardia, hypotension, fatigue, dizziness, depression, memory loss, impotence, cold limbs and, less commonly, severe hypotension, heart failure and bronchospasm. Sudden withdrawal can trigger rebound hypertension.
Mild-to-moderate elevations in serum aminotransferase levels occur in less than 2% of patients on beta-blockers and are usually transient and asymptomatic, resolving even with continuation of therapy. There is no information on the rates of ALT elevations during nebivolol therapy. Despite its use in several large clinical trials, nebivolol has not been linked to cases of clinically apparent liver injury.
Likelihood score: E (Unlikely cause of clinically apparent liver injury).
Mechanism of Injury
Nebivolol undergoes extensive metabolism by the liver, is a substrate of CYP 2D6 and its excretion is largely biliary. The liver injury linked to other beta-blockers is likely to be idiosyncratic.
|DRUG||CAS REGISTRY NUMBER||MOLECULAR FORMULA||STRUCTURE|
Top of page